title: Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C.
abstract: One of the side effects by interferon ribavirin (I/R) treatment is haemolytic anemia, causing some patients to discontinue I/R treatment. The exact mechanism of I/R-induced anemia is unknown. The aim of this study is to evaluate the effects of I/R treatment on the serum lipid and red blood cell (RBC) membrane lipid profiles of patients with chronic hepatitis C (CHC) and the association between changes of RBC membrane lipids and haemolytic anemia by I/R treatment. Fourteen patients with CHC were treated with I/R and their serum lipid profiles were studied. In addition, in seven of the 14 patients, the RBC membrane lipid profiles were analysed. In the RBC membrane lipid composition, the total cholesterol, total phospholipids and cholesterol/phospholipids (C/PL) ratio were significantly increased. Phosphatidylcholine (PC) and the phosphatidylcholine/ sphingomyelin (PC/SM) ratio were significantly decreased and other phospholipid fractions were significantly increased. Changes in the serum lipids and RBC membrane lipid profiles of patients with CHC treated with I/R were shown. Especially, a decrease in the RBC deformability and membrane fluidity by changes in these RBC membrane lipids was supposed and it is suggested that those changes may result in haemolytic anemia by I/R treatment.
authors.affiliation: 3rd Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama City 641-0015, Japan. h-tana@yf6.so-net.ne.jp
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Miyano
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Fukui
authors.forename: M
authors.initials: M
authors.lastname: Ichinose
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004910:Erythrocyte Membrane / Q000378:metabolism*; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008055:Lipids / Q000097:blood*; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism*; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects*; D017392:Thiobarbituric Acid Reactive Substances
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D008055:Lipids; D008563:Membrane Lipids; D017392:Thiobarbituric Acid Reactive Substances; D012254:Ribavirin